XNAS · Healthcare · Biotechnology
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | -1.07 | -0.90 | +15.89% | $141,000 | ✅ Beat | +8.89% | -10.08% | — |
| 2026-02-26 | Q4 2025 | -0.96 | -1.08 | -12.50% | $132,000 | ❌ Miss | -0.83% | -2.03% | -7.12% |
| 2025-11-05 |
| Q3 2025 |
| -0.89 |
| -0.34 |
| +61.80% |
| $70,570 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | -0.98 | -1.00 | -2.04% | $75,000 | ❌ Miss | +4.59% | +9.59% | +8.84% |
| 2025-02-27 | Q4 2024 | -1.00 | -0.81 | +19.00% | $72,000 | ✅ Beat | +1.57% | +3.86% | -11.84% |
| 2024-05-08 | Q1 2024 | -1.10 | -0.79 | +28.18% | $72,000 | ✅ Beat | -6.64% | -4.23% | -18.32% |
| 2024-02-27 | Q4 2023 | -1.00 | -1.35 | -35.00% | $72,000 | ❌ Miss | — | — | — |
| 2023-11-13 | Q3 2023 | -1.24 | -1.09 | +12.10% | $72,000 | ✅ Beat | +8.79% | +15.73% | +37.46% |
Showing last 8 quarters.